Last reviewed · How we verify

CR845 — Competitive Intelligence Brief

CR845 (CR845) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinin B1 receptor antagonist. Area: Dermatology / Nephrology.

phase 3 Kinin B1 receptor antagonist Bradykinin B1 receptor Dermatology / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

CR845 (CR845) — Cara Therapeutics, Inc.. CR845 is a selective kinin B1 receptor antagonist that blocks inflammatory signaling to reduce pruritus and other inflammatory symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CR845 TARGET CR845 Cara Therapeutics, Inc. phase 3 Kinin B1 receptor antagonist Bradykinin B1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinin B1 receptor antagonist class)

  1. Cara Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CR845 — Competitive Intelligence Brief. https://druglandscape.com/ci/cr845. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: